Tempo Therapeutics selected into MedTech Innovator’s highly competitive 2025 Accelerator CohortJune 9, 2025
Tempo Therapeutics Announces First Patient Dosed in Clinical Trial of TT101 For Tissue Repair in Skin Cancer SurgerySeptember 5, 2024
Tempo Therapeutics Secures Series A Financing to Advance Cutting-Edge Tissue Scaffold Products into Clinical TrialsMarch 19, 2024
